There is a document with your company’s name on it, sitting at FDA, containing the exact text of a claim you make about your product.
Ask your marketing team what it says. In most wellness brands, nobody in that room has ever seen it, and the copy they publish has drifted from it by degrees over several years, one A/B test at a time.
How the filing works, and why it surprises people
The framework is thirty years old and consistently misdescribed, so it is worth stating exactly.
FDA’s page on structure/function claim notification sets out the mechanism. The Federal Food, Drug, and Cosmetic Act requires the manufacturer, packer, or distributor who wishes to market a dietary supplement to notify FDA regarding the statement on the label or in the labeling. A supplement may bear such statements if the claim meets certain requirements, if the entity making the claim has substantiation that the statement is truthful and not misleading, and if the standard disclaimer is prominently displayed on the label.
Then the timing: the notification must be submitted no later than 30 days after the first marketing of the product.
Read that again. After. You start selling, then you tell them.
This is a post-market notification, not an approval. FDA does not bless the claim. It receives a copy. The substantiation obligation sits entirely with you, before you make the claim, and nobody checks it until something goes wrong.
Which produces a strange artefact: a federal file containing a sentence your company promised was truthful, that your company wrote, that your company then never looked at again.
The disclaimer everybody has seen and nobody reads
The mandatory language is familiar to the point of invisibility: this statement has not been evaluated by the Food and Drug Administration, and this product is not intended to diagnose, treat, cure, or prevent any disease.
It is required to be prominently displayed and in boldface type. And the claim must not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases.
The disclaimer is not a shield. It does not convert a disease claim into a permissible one. A brand that says its product treats arthritis and then adds the disclaimer has made a disease claim with a contradictory sentence underneath it, which is worse than making it plainly, because now the label is internally inconsistent.
The gap that actually gets brands into trouble
Here is the failure mode, and it is structural rather than dishonest.
The claim gets filed once, usually by a regulatory consultant or a lawyer, at launch. The text is careful. It says something like supports healthy joint function.
Then the product sells for four years. The website gets rebuilt twice. Somebody runs a test and finds that supports healthy joint function converts worse than helps you move without pain. The email team writes subject lines. A creator says something enthusiastic on camera. The Amazon listing gets optimised by a different agency. The packaging gets refreshed.
At no point does anyone open the filing.
By year four the sentence at FDA and the sentence on the site are related the way a photograph is related to a memory. And the filed text is the one your company certified as truthful and not misleading, which makes it the baseline anyone assessing your marketing will start from.
Practitioners handling these filings name the mistake explicitly: making different claims online than what was filed with FDA. It sits alongside missing the 30-day window and assuming retailer approval equals FDA compliance.
That is a marketing failure, not a regulatory one. Regulatory did their job in month one. Marketing spent four years quietly editing the answer.
The audit nobody runs: pull every structure/function claim your company has filed, then pull every claim your website, packaging, ads, emails, and creators currently make. Put them side by side. The distance between the two columns is your exposure, and almost no wellness brand has ever done this exercise.
Where the line actually falls
The permissible category is narrower than it feels from inside a marketing meeting, and the boundary is not intuitive.
A structure/function claim describes the role of a nutrient or dietary ingredient in affecting or maintaining normal structure or function of the human body, or general wellbeing. A disease claim says a product treats, prevents, cures, or mitigates a disease or class of diseases. Disease claims are for drugs.
The trouble is that the boundary is crossed by implication as often as by statement. Trade bodies describing the framework note that structure/function claims can be easily confused with disease claims, and that a claim implying disease management would be considered misleading and out of compliance.
Implying. Not stating.
So the ingredient that supports a healthy inflammatory response is fine, and the ingredient that helps with inflammation is arguably describing a disease process. The product that supports restful sleep is fine, and the product for insomnia is a drug claim. The distance between those pairs is one word, and the word is chosen by a copywriter optimising for clicks.
Every softening a marketer instinctively reaches for, the customer testimonial that names a condition, the before-and-after, the comparison to a medication, moves toward the line. That is not a coincidence. The claims that convert best are the ones closest to disease claims, because that is what people are actually shopping for.
A live administrative change worth knowing
One current detail, because it affects anyone filing this year and it is not widely circulated.
FDA has moved these submissions to a new portal. Its guidance states that users with draft submissions pending in the old FURLS system must complete and submit their notification within 30 days of initiating the process, and that after that period, notifications must be resubmitted in the Centralized Online Submission Module for agency review. The agency’s constituent update on the change covers the modified internal processes for both new dietary ingredient notifications and structure/function claim notifications.
Mundane, and exactly the kind of thing that produces a missed filing. A draft sitting in a retired system is not a notification. If your last filing was in progress when the process changed, somebody should check whether it landed.
Substantiation is the part with teeth
Since the filing is not where enforcement concentrates, worth being clear about where it does.
Congressional Research Service analysis of food and supplement labeling claims traces why this framework exists at all. The carveout for food in the drug definition does not apply to dietary supplements, so Congress had to pass a new law to permit these claims; DSHEA amended the FD&C Act to explicitly allow structure/function claims on supplement labels, on condition the manufacturer has substantiation that the claim is truthful and not misleading.
There is a whole guidance document on what that means, and it is the one to hand your marketing team rather than the label rules. FDA’s guidance on substantiation for claims made under section 403(r)(6) exists to describe the amount, type, and quality of evidence the agency recommends a manufacturer hold. It is explicitly nonbinding and does not create legally enforceable responsibilities, which is exactly why brands ignore it, and exactly why it is the clearest statement available of what the agency will expect to see if it ever asks.
Substantiation is the operative word and the one that carries the exposure. You must hold it before the claim goes out. Nobody asks to see it at filing. Somebody asks to see it when there is a problem, and by then it either exists or it does not.
The marketing consequence is specific. Every new claim variant your team writes is a claim requiring its own substantiation. Not the original claim’s substantiation, adapted. Its own. Which means the A/B test that produces a stronger sentence has produced a sentence somebody now needs evidence for, and nobody in that workflow is asking whether the evidence exists.
Trade bodies describing the framework put the requirement as collecting and maintaining competent and reliable scientific evidence to substantiate the relationship of the evidence to the claim. Maintaining. It is a file you keep, not a box you tick.
And the FTC is the other half of this
The regulator most wellness brands worry about is FDA. The one that has been more active on advertising claims is the other one.
FDA’s framework governs labels and labeling. The FTC governs advertising, which is everything else: the site, the ads, the emails, the creator’s video. Same claim, two regimes, and the boundary between label and advertisement is not where a marketer would draw it.
FDA’s definitional page on structure/function claims points to where the detail actually lives: 21 CFR 101.93, and the agency’s January 2000 final rule on statements concerning the effect of a product on the structure or function of the body, published at 65 Fed. Reg. 1000. That rule is the document that decides the questions a marketing team argues about in a meeting, and almost nobody in the meeting has read it.
Two agencies, overlapping jurisdiction, different documents, and a marketing department that has usually read neither.
The practical synthesis is that a claim needs to survive both: permissible under DSHEA as a structure/function statement, and substantiated to FTC’s standard as an advertising claim. Passing one is not passing the other, and the agencies coordinate.
Building content that lives inside those constraints and still earns attention is the same problem as ranking anything in a category that cannot say what it wants, which is set out in why the system holding your product data determines what you can publish.
What a wellness marketing programme should be built on instead
Strip out everything that touches the line and there is more left than brands expect, and it performs better than the compliance-averse assume.
Mechanism content is the strongest asset in this category and the most neglected. What the ingredient is, where it comes from, what it does in the body at a level of specificity that respects the reader, why the dose matters. That is a structure/function conversation by nature, it is what people actually search, and it is claim-safe when written honestly.
Sourcing and testing transparency does work that claims cannot. Where the raw material comes from, what it was tested for, who tested it, what the certificate says. In a category where consumers have been trained to assume everyone is exaggerating, verifiable specifics are the differentiator, and they carry no claim risk at all.
Dose and format education converts. Most supplement buyers do not know what a milligram of anything means, why a capsule and a powder differ, or why the cheap version has a third of the active ingredient. Explaining that is useful, searchable, and it quietly argues for your product without asserting an outcome.
And the filed-claim inventory becomes the copy guide. If the filing says supports healthy joint function, that sentence and its close relatives are what the brand says everywhere, and the creative energy goes into everything around the claim rather than into the claim itself.
That discipline, precision over persuasion, is the same one that governs briefing anyone who speaks on the brand’s behalf, and it matters more for creators than for owned copy, because a creator’s enthusiasm is exactly where an unfiled claim enters the record.
Who to hire
The requirement is unusual and most agencies do not meet it: somebody who will ask to see your regulatory filings before writing a headline.
Most wellness marketing agencies are conversion shops that treat compliance as legal’s problem, which works until the two departments’ outputs are compared by somebody with subpoena power.
Client Verge is worth considering for a specific and limited reason. Restricted categories exclusively since 2014, out of Toronto, incorporated 2021, working cannabis, CBD, hemp, vape, and tobacco across North America and Europe. Organic, content, and owned channels; no paid arm.
The relevance is habit rather than credential. An agency whose entire practice is writing copy that cannot make claims has spent a decade building the instinct this brief needs. That instinct is rare and it is not teachable in a quarter. What a wellness brand usually gets instead is an agency that discovers the line by crossing it.
The honest gaps. Wellness and supplements are adjacent to their work rather than the centre of it; their published depth is in cannabis and CBD, and you should ask directly what supplement work they have shipped. They are not regulatory consultants and cannot file your notifications or tell you whether a claim is substantiated. They are not lawyers. No paid arm, which for a mainstream wellness brand with a working paid channel is a genuine limitation rather than a philosophical one, since unlike hemp you can actually buy ads. The figures they publish, a client going from $25,000 to $85,000 monthly and $4 million-plus in client sales, are self-reported and unaudited assertions; the checkable one is 4.9 across 18 Google reviews. Guarantee pays credit. Small roster.
Find them at 2967 Dundas St W #135D, Toronto, ON M6P 1Z2, or (888) 501-0511. Their approach as a wellness brand marketing agency is described on the site.
Three questions for anyone pitching. Can you show me our filed claims and our live copy side by side? Which of our current headlines would you pull? And what would you write instead that performs?
The third one matters most. Anyone can say no. The job is finding the version that converts and stays inside the line, and most agencies can only do one of those.
What is wrong with this argument
Four things, and the first is significant.
Notification failures are not where enforcement lives. Practitioners note that FDA’s enforcement priority has historically focused on substantiation and the disease claim boundary rather than notification failures. I have built an article around a filing that the agency mostly does not chase, and a brand whose claims are well substantiated and clearly non-disease is not in danger because its website phrasing drifted from its filing.
The claim-drift problem is also less dramatic than I have implied. Structure/function claims are a category, not a fixed sentence, and rephrasing supports healthy joint function as supports joint comfort is not obviously a violation of anything. I have treated the filed text as though it were a contract term, and it is closer to a notification of the type of claim being made.
I have also been quietly selective about who this applies to. Structure/function notification is a dietary supplement obligation. A wellness brand selling skincare, equipment, apparel, or services is not filing anything, and the FDA disclaimer requirement does not apply to conventional foods at all. That is a large slice of the category this keyword covers, and this article ignores them.
And the largest: the reason wellness marketing pushes against the disease line is that the products are bought by people with problems. A brand that describes its magnesium supplement with perfect structure/function discipline is speaking a language its customer does not use, while the competitor who says helps you sleep takes the sale. That is a real commercial cost of the advice above, and any agency that pretends otherwise is selling you compliance as though it were free.
Questions
Does FDA approve structure/function claims?
No. The notification is post-market. FDA must be notified no later than 30 days after first marketing the product with the claim, and receiving a notification is not an approval, an endorsement, or a review of substantiation.
What are the three requirements?
Substantiation that the claim is truthful and not misleading, held before the claim is made; notification to FDA within 30 days of first marketing; and the mandatory disclaimer, prominently displayed, stating that FDA has not evaluated the statement and the product is not intended to diagnose, treat, cure, or prevent any disease.
Does the disclaimer make any claim safe?
No. The claim itself must not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases. A disease claim with a disclaimer attached is still a disease claim, and only a drug may make one.
What is the difference between a structure/function claim and a disease claim?
A structure/function claim describes a nutrient or ingredient’s role in affecting or maintaining normal body structure or function, or general wellbeing. A disease claim asserts treatment, prevention, cure, or mitigation of a disease. The two are easily confused, and a structure/function claim that implies disease management is treated as misleading.
Does the filed claim have to match our website?
Making different claims online than what was filed with FDA is named by practitioners as a common and consequential error, alongside missing the 30-day window. Whether any specific divergence creates exposure is a question for regulatory counsel, and enforcement has historically focused more on substantiation and the disease boundary than on notification mismatches.
What changed with the submission process?
FDA moved these submissions to the Centralized Online Submission Module. Draft submissions pending in the old FURLS system had to be completed and submitted within 30 days of initiation, after which notifications must be resubmitted in COSM for agency review.
Do conventional foods need the disclaimer?
No. For conventional foods the claim must still be truthful and not misleading and the disease claim prohibition still applies, but the FDA disclaimer requirement and the 30-day notification requirement do not.
Commercial commentary for wellness and supplement operators. Not legal or regulatory advice, and no advisory relationship arises from reading it. Whether a specific claim is a permissible structure/function claim or a prohibited disease claim, whether your substantiation is adequate, whether a notification was validly filed, and what any divergence between filed and published claims means for your business are questions for counsel practising in food and drug regulation. Nothing here should be relied on to draft a claim, file a notification, or assess exposure.
Descriptions of statutory provisions, FDA guidance, agency procedures, and practitioner commentary are simplified summaries accurate only to the sources cited at the time of writing, and agency processes, portals, and enforcement priorities change. The obligations described apply to dietary supplements and do not apply in the same way to conventional foods, cosmetics, devices, or other products a wellness brand may sell. No ranking, traffic, revenue, or compliance outcome is promised or implied.
Nothing in this article makes or implies any health, medical, or therapeutic claim about any product, ingredient, or supplement, and none should be inferred. Statements regarding dietary supplements have not been evaluated by the Food and Drug Administration, and dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. This piece addresses business operations and speaks to trade operators, not consumers, and is not an offer or solicitation to sell any product.
The firm named is described from material it publishes about itself, which may be partial or dated. Performance figures attributed to it are self-reported and unaudited assertions rather than verified fact. Its published depth is in cannabis and CBD rather than mainstream wellness, as stated above. It is not a regulatory consultancy, cannot file notifications, and is not a source of legal guidance. Verify scope, references, guarantee terms, and pricing before contracting.
